Roche has announced the launch of its cobas® MPX-E assay, a next generation molecular diagnostic solution designed for simultaneous 4-in-1 screening of blood donations, marking a significant advancement in transfusion safety and infectious disease detection.

The cobas MPX-E assay enables the simultaneous detection of multiple blood borne pathogens in a single test, helping blood banks and diagnostic laboratories improve screening efficiency while maintaining high standards of accuracy and reliability. The solution is built on Roche’s established molecular diagnostics platform and is intended to support early detection of infections, thereby reducing the risk of transfusion transmitted diseases.

According to the company, the assay enhances laboratory workflows by offering high throughput testing, streamlined operations, and faster turnaround times, which are critical in ensuring the timely availability of safe blood units. By consolidating multiple tests into a single assay, it also helps optimize resource utilization and operational costs for blood screening programs.

A company spokesperson stated that the launch reflects Roche’s continued commitment to advancing innovative diagnostic technologies that improve patient safety and public health outcomes. “Ensuring the safety of blood supplies is a critical priority for healthcare systems worldwide. The cobas MPX-E assay is designed to deliver reliable, efficient, and scalable screening solutions for blood donation centers,” the spokesperson noted.

The introduction of this assay comes at a time when healthcare systems globally are placing increased emphasis on strengthening blood safety protocols and enhancing diagnostic capabilities. The solution is expected to support national blood programs, hospitals, and diagnostic networks in maintaining stringent screening standards while meeting growing demand.

With this launch, Roche further strengthens its position in the global diagnostics market, leveraging cutting-edge molecular technologies to address evolving healthcare challenges and improve clinical outcomes.